A key consideration for sponsors planning to conduct decentralized clinical trials (DCTs) is the selection of appropriate clinical endpoints that are meaningful for regulators, health professionals and patients.
Considerations For Using Established Versus Novel Endpoints In Decentralized Trials
UK and US regulators explained why some established clinical endpoints are not suitable for use in decentralized trials, and discussed principles to guide the development of novel digital endpoints.
